Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2022

Conditions
Symptomatic Aortic Stenosis
Interventions
DRUG

Ticagrelor 60mg

"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."

Trial Locations (1)

36312

Hospital Alvaro Cunqueiro, Vigo

All Listed Sponsors
lead

Andres Iñiguez Romo

OTHER

NCT04331145 - Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation | Biotech Hunter | Biotech Hunter